Every parent’s worst

nightmare: knowledge and

attitudes towards meningitis

and vaccination by Cochrane, Andy et al.
8clinical review
Every parent’s worst 
nightmare: knowledge and 
attitudes towards meningitis 
and vaccination
ANDY COCHRANE (MEDICAL AFFAIRS CO-ORDINATOR), CAROLINE O’CONNOR 
(MEDICAL INFORMATION OFFICER) AND DIANE MCCONNELL (IRELAND MANAGER) 
MENINGITIS RESEARCH FOUNDATION
C
hildhood vaccination is an important and effective 
way to reduce childhood illness, disability and 
death. For example, there has been a steady decline 
in the number of cases of bacterial meningitis 
since the introduction of the vaccines that prevent 
meningococcal C disease, Haemophilus influenzae type B 
disease and the most common pneumococcal serotypes.1 
The number of cases of invasive meningococcal disease (IMD) 
caused by serogroup C has reduced from 135 in 1999 to just 
2 in 2010.1 Nevertheless, meningitis has not ‘gone away’, and 
Ireland still has the highest rates of confirmed cases of IMD in 
Europe for both of the age groups most at risk (under 5 years: 
21 per 100, 000; 15-24 year olds: 5.7: 100,000); IMD is now 
predominately caused by serogroup B2. 
A vaccine uptake rate of ? 95% is needed to achieve herd 
immunity.3 However, following the change to the immunisation 
schedule in July 2008, the uptake of the Men C and Hib 
vaccines due at 13 months fell to as low as 80% in some parts of 
the country. While there is some evidence of improved uptake 
rates4 there is a need to understand parental attitudes towards 
vaccination and knowledge about meningitis to inform 
health promotion initiatives. This is particularly important in 
advance of any future changes to the vaccination schedule 
to accommodate new vaccines (e.g., against meningococcal 
serogroup B). 
The Department of Health in England has been tracking 
parents’ attitudes towards vaccination since 19915 but 
information in Ireland is still relatively limited. There has been 
some work to explore the decline in uptake of the 12 and 13 
month vaccines. For example, a cross-sectional survey of a 
representative sample of parents in the North-West of Ireland 
indicated that some parents were choosing to both delay 
and split the administration of vaccines. Factors associated 
with poor vaccine uptake included lack of awareness of the 
schedule, not using the parent-held immunisation record and 
concerns about vaccine safety.6 
Advocating vaccination for all has been a critical part of 
our work at Meningitis Research Foundation. We work with 
health professionals and the general public to raise awareness 
about meningitis, and we have funded vital research into new 
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Meningitis Research Foundation‘s vision is a world free 
from meningitis and septicaemia. We work towards this 
vision by funding research into prevention, detection 
and treatment of the diseases, promoting education and 
awareness amongst health professionals and the public 
as well as providing support to those affected. For more 
information: 
www.meningitis.org
Dublin office: 01 819 6931
info@meningitis-ireland.org
Freefone Helpline 1800 41 33 44 
Figure 1. Parents recall of vaccines included in the Primary Childhood Schedule
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Key Findings
Primary Childhood Schedule (see Table 1)
The majority of parents were familiar with The National 
Immunisation Office booklet ‘Your child’s immunisation: a 
guide for parents’ 7 which highlights the need for five visits to 
a GP to complete a child’s immunisation in the first 13 months 
of life. However, only 30% of parents correctly stated that five 
visits were needed to complete the schedule. Furthermore, 
recall of the vaccines themselves was quite low (Figure 1), 
ranging from the 50% who mentioned the MMR, to only 16% 
who were able to recall Pneumococcal (PCV) and Hib. 
Parents were asked to name any of the diseases that 
are prevented by the primary schedule (Figure 2), and the 
relative familiarity with MMR continued; over half of the 
Table 1. Demographic information 
Age distribution of parents Marital status
16-19 20-24 25-29 30-
34
35-39 40+ Married Co-
habiting
Single 
parent
Not 
disclosed
1% 11% 20% 39% 27% 3% 51% 30% 15% 5%
Region Social class
Dublin Rest of 
Leinster
Munster Connaught ABC1F50+ C2DEF50- Not disclosed
27% 30% 23% 17% 46% 47% 7%
vaccines (see Box 1). We have recognised the need to gain 
an insight into the views of parents to guide our work. We 
therefore conducted a survey of parents with young children 
designed to assess awareness and knowledge of meningitis 
and prevention of the disease through vaccination. Telephone 
interviews were conducted using structured questionnaires of 
a nationally representative sample of parents with one or more 
children under 24 months (n = 350: 85% mothers). Nearly three 
quarters of the parents (73%) also had a child/children over 2 
years of age. Table 1 presents further demographic details of 
the sample. The vaccine-related questions in the survey were 
focussed on the current (i.e., post 2008) vaccination schedule 
and therefore related primarily to the youngest child in the 
family. 
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respondents mentioned measles (60%), mumps (53%) and 
rubella (52%). Meningitis was named by 59% (7% of whom 
specifically mentioned meningitis C). The follow-up question 
asked the parents which of the childhood infectious diseases 
worried them the most in relation to their own child/children. 
Meningitis emerged as the most worrying disease for nearly 
two-thirds of the parents (62%), followed by measles (33%). 
The justifiable concern about measles may be explained, 
in part, by the media coverage of the measles outbreak in 
England and Wales that occurred during the data collection 
period (March/April 2013). 
Vaccine Uptake: 
The majority (91%) of parents stated that their child/children 
were up to date with their immunisations. Of those with a child 
eligible for the vaccine scheduled at 12 and 13 months, only 
90% (n = 216) had taken their child for the 12 month visit (MMR 
& PCV ) and only 81% (n=203) for the vaccines scheduled at 13 
months (MenC and Hib) at the time of the survey. These figures 
are slightly lower than the uptake rates reported by the Health 
Protection and Surveillance Centre (HPSC) which range from 
87-96% for the vaccines due at 12 and 13 months.4 A possible 
explanation for the difference is that the survey findings may 
take into account parents delaying, rather than defaulting, the 
immunisations due at 12 and 13 months. Similar to the findings 
in England5, the child being unwell at the time was given as the 
main reason for missing the appointments. Comments from 
the respondents suggested that the immunisations may still be 
completed, but later than scheduled:
“She was sick for a while and she’s missed a couple so she behind 
on some of them and we can catch up on them next time.”
Nevertheless, the lower uptake rates for the fourth and fifth 
visits and delays in completing the primary schedule leave 
children vulnerable to life-threatening diseases including 
meningitis when they are most at risk.8 In an attempt to 
understand this phenomenon, the respondents were 
presented with an additional list of possible reasons why the 12 
and 13 month vaccines might be missed or delayed (Table 2), 
and asked to indicate how important these were as potential 
reasons, using a Likert-type scale. While none of the reasons 
emerged as a central explanatory factor, it could be that an 
improved reminder system and education about the need to 
complete the schedule on time may be worth exploring. 
“I think it completely slipped my mind until I got a reminder, so I 
had to rearrange for another visit.”
“Every time I had the appointment he always got sick and I keep 
forgetting to make the appointment.”
Table 2. Potential reasons for missing 12 and 13 month 
visits
% indicating statement 
is  important/very 
important
(n = 350) 
No reminder received from 
GP
34
Parent not available to take 
the baby
33
Easy to forget 29
Not aware that fifth visit was 
needed
26
Prefer to wait until child is 
older
26
Inconvenient/inflexible 
appointment times
25
Only a booster so not really 
needed
21
Figure 2. Parents recall of vaccine preventable disease and the most worrying 
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Make an impact on 
COPD exacerbations
•  SPIRIVA® Respimat® 5 μg
 –   Demonstrated a 31% reduction in relative risk of having at least one COPD exacerbation (p<0.0001) vs control in one year*1,2
 –   Showed a 27% reduction in relative risk of hospitalisation due to COPD exacerbation (p<0.005) vs control in one year*1,2
 –   Is the only non-dry powder LAMA inhaler for the treatment of COPD symptoms2,3
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There does seem to 
be some scope in 
enhancing the role of 
the practice nurse as a 
source of information, 
as [they] were 
mentioned by very few 
parents. 
The current schedule requires a baby to receive at least two 
separate injections at each visit (three are needed at 6 months); 
any changes to the schedule may mean more injections are 
necessary. Nearly two thirds of the parents surveyed felt 
that two injections were the maximum acceptable at any 
one time, and only 3% would accept “as many as necessary” 
(Figure 3). This is an important issue as parental perceptions of 
acceptability are likely to be important factors in uptake rates if 
the number of injections needed per visit is increased.
Knowledge of meningitis 
The survey findings indicated that parents tend to rely on 
their family doctor, and, to a lesser extent, the public health 
nurse (Table 2) for information about both vaccination and 
meningitis. There does seem to be some scope in enhancing 
the role of the practice nurse as a source of information, 
as these health professionals were mentioned by very few 
parents. Only a small number of parents reported that they 
were seeking information on the internet; the website most 
commonly cited was ‘Google’ which is a little worrying as some 
parents may be accessing unreliable sources of information.
Table 2. ‘Best’ sources of information (%) about 
vaccination and meningitis
Vaccination (% 
n= 350)
Meningitis (% n 
= 350)
Family doctor 44 43
Practice nurse 7 4
Public health 
nurse
35 18
Midwife 6 2
HSE publications 10 9
Media 2 9
Websites 11 13
Other 15 17
NB. Parents could select more than 1 response
The majority of the parents had no direct experience of 
meningitis (86%), but more than half (53%) were confident 
that they could recognise the signs and symptoms of the 
disease. There was less confidence in the ability to recognise 
the signs and symptoms associated with septicaemia (28%). 
Given the relative lack of experience with both meningitis 
Figure 3: Acceptable number of injections per visit
65%
17%
15%
3%
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and septicaemia, it is probably unsurprising that the level of 
knowledge of the different causes of meningitis was quite 
low. More than half (58%) could not name a particular cause/ 
organism associated with meningitis; furthermore, there 
did not seem to be a clear link between the vaccines and 
the disease they prevent. For example, only 11% mentioned 
‘meningitis C’ as a potential cause compared to 21% who 
named MenC when asked to list the vaccines included in 
the schedule. More worryingly, over a third of parents (37%) 
mistakenly believed that on completion of the primary 
childhood immunisation schedule their child would be 
fully protected against all types of meningitis. This lack of 
knowledge contrasts with the high level of concern associated 
with the disease; specifically, 48% strongly agreed with 
the statement “I am concerned about my child contracting 
meningitis” and meningitis emerged as the most worrying of 
the childhood infectious diseases.
Conclusions
Meningitis creates a high level of concern for parents, yet 
some parents have ‘missed’ or ‘delayed’ completion of the 
immunisation schedule leaving their children unprotected at 
a period when they are most vulnerable. There appears to be 
a generally low level of knowledge amongst this sample of 
parents regarding the vaccines themselves and the diseases 
they protect against, which may, in part, explain a lack of 
understanding of why it is important to “get vaccines on time 
every time”7. Encouragingly more than half of parents were 
confident about recognising the early signs/symptoms of 
meningitis, but there was poor understanding of the different 
bacterial/viral causes of the disease; over half could not name 
a single type. Perhaps unsurprisingly, therefore, over a third 
of parents mistakenly believed that the current vaccination 
schedule protects their child against all forms of meningitis. 
Some parents may not, therefore, consider the possibility of 
meningitis if their child presents with the early symptoms of 
the disease resulting in delays in vital treatment. 
The findings indicate that there is an ongoing need for 
information about vaccination and meningitis at a national 
level, for example the National Immunisation Office “Every 
vaccine is a little victory” campaign, and our own work 
including our annual Meningitis Awareness Week (15th-22nd 
September 2013). There is of course, also a need for more 
tailored individualised information. Face-to-face education 
sessions with parents are one strategy that may improve 
vaccination rates and parental knowledge. However, a recent 
systematic review7 concluded that, given the limited evidence 
available of the effectiveness of such sessions, it may be more 
appropriate to incorporate communication about vaccination 
into a healthcare encounter, rather than conduct it as a 
separate activity. Nurses working in general practice, therefore, 
have an important health education role to play in this regard; 
each encounter with parents is an opportunity to discuss 
vaccinations, and the life-threatening illnesses they do and 
importantly do not, prevent. 
Meningitis and septicaemia are devastating diseases; 
they can kill within hours and those who survive may be left 
with life altering after effects. Vaccination is one of the most 
important public health interventions for protecting the 
population from this and other serious diseases. The Meningitis 
Research Foundation working with the National Immunisation 
Office, other departments of the HSE and individual health 
professionals can and should work together to improve 
parental knowledge and understanding and ensure children 
and young people are protected from preventable diseases.
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